Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC Combined With Toripalimab and Donafenib in Advanced Biliary Tract Cancer
NCT05350943Phase 2Unknown
- Start
- Mar 2022
- Primary completion
- Nov 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab and donafenib in biliary tract cancer (BTC). Primary endpoint: Objective Response Rate at 2 years. Status: unknown.
02
Drugs
toripalimabdonafenib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05350943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05350943.